Assessment of frequency dependency of the class III effects of almokalant: A study using programmed stimulation and recording of monophasic action potetials and ventricular paced QT intervals

Cardiovascular Drugs and Therapy

Volumn 10, Issue 5, 1996, Pages 539-547

  Darpö, Börje ^a,c   Almgren, Olle ^b   Bergstrand, Robert ^b   Franzén, Stefan ^b   Edvardsson, Nils ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Almokalant; Class III antiarrhythmic drugs; Frequency dependence; Monophasic action potentials; Ventricular paced QT intervals

Indexed keywords

ALMOKALANT; ANTIARRHYTHMIC AGENT;

ADULT; ARTICLE; DRUG BLOOD LEVEL; HEART CYCLE; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; REGRESSION ANALYSIS;

ACTION POTENTIALS; ADULT; ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROPANOLAMINES;

EID: 0029950448     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00050994     Document Type: Article

References (30)

1. + current by almokalant in rabbit ventricular myocytes. Circ Res 1993;73:857-868.
2. Wettwer E, Grundke M, Ravens U. Differential effects of the new class III antiarrhythmic agents almokalant, E-4031 and D-sotalol, and of quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Cardiovasc Res 1992; 26:1145-1152.
3. Singh B, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol 1994;9:12-22.
4. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-690.
5. Nattel S, Zeng FD. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1984;229:283-291.
6. Nademanee K, Stevenson WG, Weiss JN, et al. Frequency-dependent effects of quinidine on the ventricular action potential and QRS duration in humans. Circulation 1990;81: 790-796.
7. k blocking agent, on ventricular repolarization and on sino-atrial and atrioventricular nodal function in the heart. A study in healthy, male volunteers utilizing transesophageal atrial stimulation. J Cardiovasc Pharmacol 1995;25:681-690.
8. k blocker almokalant exhibits class III-specific effects on the repolarization and refractoriness of the human heart. A study in healthy volunteers using right ventricular monophasic action potential recordings. J Cardiovasc Pharmacol 1995;26:530-540.
9. Hirsch I, Edvardsson N, Olsson SB. Computerized analysis of monophasic action potentials from the human heart. World Congress on Medical Physics and Biomedical Engineering, Hamburg, 1982, abstract.
10. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarizations. Cardiovasc Res 1993;272: 186-193.
11. Verduyn SC, Vos MA, van der Zande J, Wellens H. A comparison between the pro-arrhythmic effect of almokalant and D-sotalol in an animal model of torsade de pointes arrhythmia. J Am Coll Cardiol 1995;(suppl):170A.
12. Carlsson L, Drews L, Duker G, Schiller-Linhardt G. Attenuation of proarrhythmias related to delayed repolarization by low dose lidocaine in the anesthetized rabbit. J Pharmacol Exp Ther 1993;267:1076-1080.
13. Carlsson L, Abrahamsson C, Almgren O, Lundberg C, Duker G. Prolonged action potential duration and positive inotropy induced by the novel class III antiarrhythmic agent H 234/09 (almokalant) in isolated human ventricular muscle. J Cardiovasc Pharmacol 1991;16:882-887.
14. Duker G, Almgren O, Carlsson L. Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anaesthetized dog. J Cardiovasc Pharmacol 1992;20:458-465.
15. k blocking drugs, UK-68,789 (dofetilide) and E-4031. Cardiovasc Res 1993;27:861-867.
16. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990;96:195-215.
17. Wiesfeld A, Crijns H, Tobé TJM, et al. Electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic, in patients with healed or healing myocardial infarcts and complex ventricular arrhythmias. Am J Cardiol 1992;70:990-996.
18. Darpö B, Edvardsson N. The effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias. A study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. J Cardiovasc Pharmacol 1995;26:198-206.
19. Ohler A, Amos G, Wettwer E, Ravens U. Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: No evidence for "reverse use dependent" block. Naunyn Schmiedebergs Arch Pharmacol 1994;349:602-610.
20. + current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 1993;7:599-604.
21. Ohler A, Ravens U. Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles. J Pharmacol Exp Ther 1994;270:460-465.
22. + current by dofetilide. Circ Res 1993;72:75-83.
23. Sawanobori T, Adaniya H, Namiki T, Hiraoka M. Rate-dependent effects of sematilide on action potential duration in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther 1994;271:302-310.
24. Schmitt C, Brachmann J, Karch M, et al. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle. Am J Cardiol 1991;68:1183-1187.
25. Yuan S, Wohlfart B, Rasmussen HS, Olsson SB, Blomström-Lundqvist C. Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. A study using simultaneous monophasic action potential recordings from two sites in the right ventricle. Eur Heart J 1994;15: 514-22.
26. Olsson SB, Edvardsson N. Clinical electrophysiological study of antiarrhythmic properties of flecainide: Acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimulation. Am Heart J 1981;102:864-71.
27. Milne JR, Ward DE, Spurell RAJ, Camm AJ. The ventricular paced QT interval - the effects of rate and exercise. PACE 1982;5:352-358.
28. Edvardsson N, Olsson SB. Induction of delayed repolarization during chronic beta-receptor blockade. Eur Heart J 1985;6(Suppl D):163-169.
29. Morgan JM, Cunningham D, Rowland E. Dispersion of action potential duration: Demonstrable in humans after premature ventricular extra stimulation but not in steady state. J Am Coll Cardiol 1992;19:1244-1253.
30. Morgan J, Cunningham D, Rowland E. Electrical restitution in the endocardium of the intact human right ventricle. Br Heart J 1992;67:42-46.